Institutional Specialty

Many Teams One Destination

Ready Set Success

Institutional Specialty

Ready Set Success

POA One 2008

Many Teams One Destination

POA One 2008

the proof is lifeFocused on the best clinical picture

ion H E A L T H C A R E

2

Concept#1 - ION/atom

I N S P I R A T I O N G R O W S

© 2001 The GlaxoSmithKline Group of CompaniesCAV/CAV/000009 All rights reserved.Printed in USA. October 2001.

PROGRESSRISES FROM A SINGLE VISION…

To support and nurture

the discovery and

distribution of knowledge

in the cardiovascular

sciences on a global basis—

by uniting scientific

endeavor, education

and creativity.

Lifesaving Science. It’s more than our job....It’s our mission.™

A N N O U N C I N GThe GlaxoSmithKline Research & Education

Foundation for Cardiovascular Disease

job....It’s our mission.™

THE GENOMICS EDUCATIONAL WORKSHOP

The Genomics Educational Workshop will provide participants

with up-to-date techniques to research approaches related to evolving

technologies in cardiology. The workshop, to be held in Philadelphia

in June 2002, is offered free of charge to members of the medical

community. Attendees will assume responsibility for their own travel

and lodging expenses. The Foundation will sponsor the travel and

hotel costs for 20 young investigators (fellows or junior faculty)

nominated by their mentors and selected on a merit basis by an

independent panel of Foundation Advisory Board members.

More information is available online at www.cvfoundation.org

Lifesaving Science. It’s more than our job....It’s our mission.™

I O N G R O W S

Developed for efficacy, designed for safety

Favorable composition of PLA provides

long-lasting results

• Microparticles are gradually broken down

and eliminated by normal metabolic pathways

• Slow resorption due to high molecular weight

and crystalline structure

New-Fill®—stable reconstitution for effective administration

• Held within a well-tested emulsifying

and thickening agent

• Injected deep intradermally or

subcutaneously through

a 26 G needle1

• Requires no skin test2

ReshapeRestore

Renew

T O R E ~ R E N E W ~ R E S H A P E ~ R E S T O R E ~ R E N E W

Hycamtin is contraindicated in patients with a history of hypersensitivity to topotecan or to any of its ingredients. Hycamtin should not be used in patients who are pregnant,breast-feeding or those with severe bone marrow depression. The most common serious adverse event is myelosuppression.

Please see following page for brief summary of prescribing information, includingwarnings, precautions and adverse events.

In the treatment of

relapsed ovarian and relapsed small cell lung cancer*…

*Hycamtin is indicated for the treatment of metastatic carcinoma of the ovary after failureof initial or subsequent chemotherapy, and for small cell lung cancer sensitive diseaseafter failure of first-line chemotherapy. In clinical studies submitted to support approval,sensitive disease was defined as disease responding to chemotherapy but subsequentlyprogressing ≥60 days (in the phase 3 study) or ≥90 days (in phase 2 studies) afterchemotherapy. †Hycamtin, as a single agent, is the most frequently prescribed second-lineagent for ovarian and small cell lung cancer (Tandem Cancer Audit, MAT 6/01).

A first choicefor a

second chance†

9nine

nine

sevennine

oneonezero7 00